首页> 外文期刊>British Journal of Clinical Pharmacology >Influence of ABCB1 gene polymorphisms on the pharmacokinetics of verapamil among healthy Chinese Han ethnic subjects.
【24h】

Influence of ABCB1 gene polymorphisms on the pharmacokinetics of verapamil among healthy Chinese Han ethnic subjects.

机译:ABCB1基因多态性对维拉帕米在健康的中国汉族人群中药代动力学的影响。

获取原文
获取原文并翻译 | 示例
       

摘要

AIMS: To assess the association between polymorphisms of the ABCB1 gene and the pharmacokinetics of verapamil among healthy Chinese Han ethnic subjects. METHODS: Based on polymorphisms of the ABCB1 gene at positions 2677 and 3435, 24 healthy male participants were divided into three groups: 2677GG/3435CC (n = 6), 2677GT/3435CT (n = 12) and 2677TT/3435TT (n = 6). Each subject had received a single oral dose of verapamil (80 mg) under fasting conditions. Multiple blood samples were collected over 24 h, and plasma concentrations of verapamil were determined by HPLC. Pharmacokinetic characteristics were compared between the different genotypic groups. RESULTS: The pharmacokinetics parameters of verapamil differed significantly among the three genotypic groups. AUC(last) was significantly lower among individuals with the 2677TT/3435TT (159.5 +/- 79.0 ng ml(-1) h) and 2677GT/3435CT (189.3 +/- 73.1 ng ml(-1) h) genotypes than those with the 2677GG/3435CC genotype (303.1 +/- 83.7 ng ml(-1) h) (P= 0.004 and P= 0.008, respectively). However, the CL/F value was higher among subjects with the 2677TT/3435TT (523.0 +/- 173.7 l h(-1)) genotype than those with the 2677GT/3435CT (452.2 +/- 188.6 l h(-1)) or 2677GG/3435CC (265.4 +/- 72.8 l h(-1)) genotypes. A significant difference was also found between the latter two groups (P= 0.034). In addition, the C(max) tended to be higher among subjects with the 2677GG/3435CC genotype than those with the 2677GT/3435CT or 2677TT/3435TT genotypes (42.2 +/- 3.9 vs 32.2 +/- 16.2 vs 38.1 +/- 13.7 ng ml(-1)). CONCLUSIONS: Our study showed for the first time that verapamil pharmacokinetics may be influenced by particular genetic polymorphisms of the ABCB1 gene among healthy Chinese Han ethnic subjects. An individualized dosage regimen design incorporating such information may improve the efficacy of the drug whilst reducing adverse reactions.
机译:目的:评估健康汉族人群中ABCB1基因多态性与维拉帕米药代动力学之间的关联。方法:根据ABCB1基因在2677和3435位的多态性,将24名健康男性参与者分为三组:2677GG / 3435CC(n = 6),2677GT / 3435CT(n = 12)和2677TT / 3435TT(n = 6) )。每个受试者在禁食条件下均接受了一次口服维拉帕米(80 mg)口服治疗。在24小时内收集了多个血液样本,并通过HPLC测定了维拉帕米的血浆浓度。比较了不同基因型组之间的药代动力学特征。结果:在三个基因型组中,维拉帕米的药代动力学参数存在显着差异。基因型2677TT / 3435TT(159.5 +/- 79.0 ng ml(-1)h)和2677GT / 3435CT(189.3 +/- 73.1 ng ml(-1)h)基因型的个体中AUC(last)显着降低2677GG / 3435CC基因型(303.1 +/- 83.7 ng ml(-1)h)(分别为P = 0.004和P = 0.008)。然而,在2677TT / 3435TT(523.0 +/- 173.7 lh(-1))基因型的受试者中,CL / F值高于2677GT / 3435CT(452.2 +/- 188.6 lh(-1))或2677GG受试者的CL / F值/ 3435CC(265.4 +/- 72.8 lh(-1))基因型。在后两组之间也发现了显着差异(P = 0.034)。此外,具有2677GG / 3435CC基因型的受试者的C(max)倾向于高于具有2677GT / 3435CT或2677TT / 3435TT基因型的受试者的C(max)(42.2 +/- 3.9 vs 32.2 +/- 16.2 vs 38.1 +/- 13.7 ng ml(-1))。结论:我们的研究首次表明,健康汉族人群中维拉帕米的药代动力学可能受ABCB1基因特定遗传多态性的影响。结合了此类信息的个性化剂量方案设计可以提高药物的疗效,同时减少不良反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号